{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":8,"sponsored":0,"items":[{"id":"n_zwzoxeakidpqw3dc6mza","seq":1345727,"kind":"article","title":"Santé en Algérie : ce que prévoit l’accord signé entre le ministère et Boehringer Ingelheim","title_en":"Health in Algeria: what the agreement signed between the ministry and Boehringer Ingelheim provides","url":"https://www.algerie360.com/avc-ministere-sante-boehringer-ingelheim","summary":"L’Algérie renforce ses efforts pour améliorer la prise en charge des accidents vasculaires cérébraux (AVC) et des maladies rares. Le ministère de la Santé et […] L’article Santé en Algérie : ce que prévoit l’accord signé entre le ministère et Boehringer Ingelheim est apparu en premier sur .","published":"2026-10-02T12:42:44Z","seen":"2026-10-02T12:55:56Z","lang":"fr","country":"DZ","source":{"id":"kite-algerie360-com-e63d62","name":"algerie360.com","domain":"algerie360.com","outlet":{"wikidata":"Q120167298","name":"Algérie 360","type":"website","country":"DZ","designations":["news website"]}},"via":"kite-algerie360-com-e63d62","topics":["santé","a la une"],"authors":["Wissam"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"}],"image":"https://www.algerie360.com/wp-content/uploads/2026/10/IMG_3459-scaled.webp","story":"st_zwzoxeakidpqw3dc6mza","category":"health","category_p":0.68,"category2":"economy-business","sentiment":"neutral","tone":0.25,"political":0.22},{"id":"n_ar5zd5lduuh6b2fk3k3q","seq":1333219,"kind":"article","title":"لدعم مرضى السكتة الدماغية.. وزارة الصحة توقع اتفاقية مع شركة بوهرنجر إنجلهايم","title_en":"To support stroke patients.. The Ministry of Health signs an agreement with Boehringer Ingelheim","url":"https://www.ennaharonline.com/%d9%84%d8%af%d8%b9%d9%85-%d9%85%d8%b1%d8%b6%d9%89-%d8%a7%d9%84%d8%b3%d9%83%d8%aa%d8%a9-%d8%a7%d9%84%d8%af%d9%85%d8%a7%d8%ba%d9%8a%d8%a9-%d9%88%d8%b2%d8%a7%d8%b1%d8%a9-%d8%a7%d9%84%d8%b5%d8%ad%d8%a9","summary":"أشرف وزير الصحة، البروفيسور محمد صديق آيت مسعودان، رفقة المدير العام الإقليمي لمنطقة IMETA (الهند والشرق الأوسط وتركيا وأفريقيا)، ديريك أوليري، الخميس، بمقر الوزارة، على مراسم إمضاء اتفاقية تعاون بين وزارة الصحة وشركة «بوهرنجر إنجلهايم» (Boehringer Ingelheim)، تهدف إلى دعم جهود الوزارة في مجال التكفل بالسكتة الدماغية والأمراض النادرة. وحسب بيان وزارة الصحة، أمضت الاتفاقية […] The post لدعم مرضى السكتة الدماغية.. وزارة الصحة توقع اتفاقية مع شركة بوهرنجر إنجلهايم appeared…","published":"2026-10-02T10:07:46Z","seen":"2026-10-02T11:52:53Z","lang":"ar","country":"DZ","source":{"id":"kite-ennaharonline-com-674fcb","name":"ennaharonline.com","domain":"ennaharonline.com","outlet":{"wikidata":"Q3054447","name":"Ennahar newspaper","type":"newspaper","designations":["daily newspaper"]}},"via":"kite-ennaharonline-com-674fcb","topics":["الوطني"],"authors":["عايدة عبد الحي"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"}],"story":"st_ar5zd5lduuh6b2fk3k3q","category":"health","category_p":0.8,"sentiment":"positive","tone":0.39,"political":0.04},{"id":"n_xargko2vegseja4bdgqa","seq":1312638,"kind":"article","title":"وزارة الصحة تمضي اتفاقية تعاون مع شركة بوهرنجر إنجلهايم","title_en":"Ministry of Health signs a cooperation agreement with Boehringer Ingelheim","url":"https://www.elbilad.net/national/%D9%88%D8%B2%D8%A7%D8%B1%D8%A9-%D8%A7%D9%84%D8%B5%D8%AD%D8%A9-%D8%AA%D9%85%D8%B6%D9%8A-%D8%A7%D8%AA%D9%81%D8%A7%D9%82%D9%8A%D8%A9-%D8%AA%D8%B9%D8%A7%D9%88%D9%86-%D9%85%D8%B9-%D8%B4%D8%B1%D9%83%D8%A9-%D8%A8%D9%88%D9%87%D8%B1%D9%86%D8%AC%D8%B1-%D8%A5%D9%86%D8%AC%D9%84%D9%87%D8%A7%D9%8A%D9%85-146013","published":"2026-10-02T09:50:39Z","seen":"2026-10-02T09:50:39Z","lang":"fr","country":"DZ","source":{"id":"kite-elbilad-net-b6da4b","name":"elbilad.net","domain":"elbilad.net","outlet":{"wikidata":"Q3049742","name":"El Bilad","type":"newspaper","country":"DZ","designations":["daily newspaper"]}},"via":"kite-elbilad-net-b6da4b","entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"}],"story":"st_xargko2vegseja4bdgqa","category":"health","category_p":0.57,"category2":"economy-business","sentiment":"positive","tone":0.48,"political":0.08},{"id":"n_odd5oew2qtpjmn3pkv4a","seq":1089015,"kind":"article","title":"Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69726969-zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvement-399.htm","published":"2026-10-01T08:33:23Z","seen":"2026-10-01T08:33:23Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.76,"sentiment":"positive","tone":0.03,"political":0.02},{"id":"n_f4k4emu4x3ixa7bdgtca","seq":1087516,"kind":"article","title":"Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.chathamdailynews.ca/press-releases/globe-newswire/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes","published":"2026-10-01T07:33:00Z","seen":"2026-10-01T08:32:12Z","lang":"en","country":"CA","source":{"id":"chathamdailynews.ca","name":"chathamdailynews.ca","domain":"chathamdailynews.ca","outlet":{"wikidata":"Q126490070","name":"The Chatham Daily News","type":"newspaper","designations":["local newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.78,"sentiment":"positive","tone":0.13,"political":0.01},{"id":"n_szp2xjwbeo7ricccmnlq","seq":1080483,"kind":"press_release","title":"Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.globenewswire.com/news-release/2026/10/01/3372564/0/en/boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-d.html","summary":"Ingelheim, Germany - Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with obesity or overweight and type 2 diabetes (T2D). 1 The trial met its co-primary endpoints, which were % change in body weight from baseline and body weight reduction of ≥5% from baseline, using both the treatment-regimen* and efficacy estimands † . 1 After…","published":"2026-10-01T07:30:00Z","seen":"2026-10-01T07:53:25Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"image":"https://ml-eu.globenewswire.com/Resource/Download/d5e21fe1-beec-4d8a-8d99-4b080026b68f","story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.78,"sentiment":"positive","tone":0.52,"political":0.01},{"id":"n_p3tzxf4zj7upivtww2ka","seq":1079717,"kind":"press_release","title":"Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes","url":"https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html","summary":"Company announcement – No. 52 / 2026","published":"2026-10-01T07:30:00Z","seen":"2026-10-01T07:52:04Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","copenhagen:zeal","dk0060257814","7716"],"entities":[{"id":"Q18552286","name":"Zealand Pharma","type":"org"},{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"},{"id":"Q123907235","name":"survodutide","type":"other"}],"mentions":2,"story":"st_szp2xjwbeo7ricccmnlq","category":"health","category_p":0.77,"sentiment":"positive","tone":0.48,"political":0.02},{"id":"n_lz3lv2udw5lbj3qtkgla","seq":655155,"kind":"article","title":"Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million","url":"https://www.finanznachrichten.de/nachrichten-2026-09/69704151-boehringer-ingelheim-investments-into-sustainability-related-programs-and-health-partnerships-to-reach-eur-500-million-399.htm","published":"2026-09-29T11:26:34Z","seen":"2026-09-29T11:26:34Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","science","security","business"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q699532","name":"Boehringer Ingelheim","type":"org"}],"story":"st_us5hzvhgmh7qvmqyzjoq","category":"economy-business","category_p":0.88,"sentiment":"positive","tone":0.51,"political":0.12}]}